Advanced

Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus : Results from the SLICC Inception Cohort

Wirestam, Lina; Enocsson, Helena; Skogh, Thomas; Padyukov, Leonid; Jönsen, Andreas LU ; Urowitz, Murray B.; Gladman, Dafna D.; Romero-DIaz, Juanita; Bae, Sang Cheol and Fortin, Paul R., et al. (2019) In Journal of Rheumatology 46(5). p.492-500
Abstract

Objective. In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes. Methods. We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analyzed for OPN... (More)

Objective. In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes. Methods. We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analyzed for OPN using ELISA. Disease activity and damage were assessed at each annual followup visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively. Results. Compared to controls, baseline OPN was raised 4-fold in SLE cases (p < 0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI ≥ 1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrollment into the cohort (r = 0.27, p < 0.0001), and patients with high disease activity (SLEDAI-2K ≥ 5) had raised serum OPN (p < 0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p = 0.0006), in cases with renal involvement (p < 0.0001) and impaired estimated glomerular filtration rate (p = 0.01). Conclusion. The performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrollment, as well as over time.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biomarkers, Disease Activity, Organ Damage, Osteopontin, Prognosis, Systemic Lupus Erythematosus
in
Journal of Rheumatology
volume
46
issue
5
pages
492 - 500
publisher
J Rheumatol Publ Co
external identifiers
  • scopus:85065255644
ISSN
0315-162X
DOI
10.3899/jrheum.180713
language
English
LU publication?
yes
id
75a564f3-2ebf-43ff-9b2b-49b0d3bb51e2
date added to LUP
2019-05-28 11:56:59
date last changed
2019-06-11 04:07:06
@article{75a564f3-2ebf-43ff-9b2b-49b0d3bb51e2,
  abstract     = {<p>Objective. In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes. Methods. We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analyzed for OPN using ELISA. Disease activity and damage were assessed at each annual followup visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively. Results. Compared to controls, baseline OPN was raised 4-fold in SLE cases (p &lt; 0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI ≥ 1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrollment into the cohort (r = 0.27, p &lt; 0.0001), and patients with high disease activity (SLEDAI-2K ≥ 5) had raised serum OPN (p &lt; 0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p = 0.0006), in cases with renal involvement (p &lt; 0.0001) and impaired estimated glomerular filtration rate (p = 0.01). Conclusion. The performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrollment, as well as over time.</p>},
  author       = {Wirestam, Lina and Enocsson, Helena and Skogh, Thomas and Padyukov, Leonid and Jönsen, Andreas and Urowitz, Murray B. and Gladman, Dafna D. and Romero-DIaz, Juanita and Bae, Sang Cheol and Fortin, Paul R. and Sanchez-Guerrero, Jorge and Clarke, Ann E. and Bernatsky, Sasha and Gordon, Caroline and Hanly, John G. and Wallace, Daniel and Isenberg, David A. and Rahman, Anisur and Merrill, Joan and Ginzler, Ellen and Alarcón, Graciela S. and Chatham, W. Winn and Petri, Michelle and Khamashta, Munther and Aranow, Cynthia and MacKay, Meggan and Dooley, Mary Anne and Manzi, Susan and Ramsey-Goldman, Rosalind and Nived, Ola and Steinsson, Kristjan and Zoma, Asad and Ruiz-Irastorza, Guillermo and Lim, Sam and Kalunian, Ken and Inanc, Murat and Van Vollenhoven, Ronald and Ramos-Casals, Manuel and Kamen, Diane L. and Jacobsen, Søren and Peschken, Christine and Askanase, Anca and Stoll, Thomas and Bruce, Ian N. and Wetterö, Jonas and Sjöwall, Christopher},
  issn         = {0315-162X},
  keyword      = {Biomarkers,Disease Activity,Organ Damage,Osteopontin,Prognosis,Systemic Lupus Erythematosus},
  language     = {eng},
  number       = {5},
  pages        = {492--500},
  publisher    = {J Rheumatol Publ Co},
  series       = {Journal of Rheumatology},
  title        = {Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus : Results from the SLICC Inception Cohort},
  url          = {http://dx.doi.org/10.3899/jrheum.180713},
  volume       = {46},
  year         = {2019},
}